507 related articles for article (PubMed ID: 21878838)
21. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
Khoury JA; Storch GA; Bohl DL; Schuessler RM; Torrence SM; Lockwood M; Gaudreault-Keener M; Koch MJ; Miller BW; Hardinger KL; Schnitzler MA; Brennan DC
Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
26. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
27. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
[TBL] [Abstract][Full Text] [Related]
28. Delayed-onset primary cytomegalovirus disease after liver transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
30. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
31. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
32. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
[TBL] [Abstract][Full Text] [Related]
35. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
36. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
37. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.
Scott GM; Naing Z; Pavlovic J; Iwasenko JM; Angus P; Jones R; Rawlinson WD
J Clin Virol; 2011 Aug; 51(4):229-33. PubMed ID: 21641274
[TBL] [Abstract][Full Text] [Related]
38. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
Večerić-Haler Ž; Bizjak B; Romozi K; Arnol M
Clin Nephrol; 2017 Supplement 1; 88(13):126-130. PubMed ID: 28601128
[TBL] [Abstract][Full Text] [Related]
39. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.
San Juan R; Yebra M; Lumbreras C; López-Medrano F; Lizasoain M; Meneu JC; Delgado J; Andrés A; Aguado JM
Clin Transplant; 2009; 23(5):666-71. PubMed ID: 19689451
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
